ArticleJournal of microbiology and biotechnology2025
Immunomodulatory Effects of LSI312A on Dendritic Cells: A Novel Approach to Modulating Inflammatory Pathways.
Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation plays a crucial role in the pathogenesis of various diseases, necessitating the development of effective anti-inflammatory therapeutics. Dendritic cells (DCs), as professional antigen-presenting cells, are key regulators of immune responses. In this study, we investigated the immunomodulatory effects of LSI312A, a novel compound derived from medicinal plant analogues, on DC function and inflammatory signaling pathways. LSI312A exhibited no cytotoxicity in DC2.4 cells at concentrations up to 20 μM. LSI312A significantly reduced antigen uptake and impaired the expression of co-stimulatory molecules, particularly MHC class II and CD40, upon lipopolysaccharide (LPS) stimulation. Moreover, LSI312A markedly suppressed the secretion of pro-inflammatory cytokines, including TNF-α and IL-6, and decreased nitric oxide (NO) production by downregulating iNOS expression at both the mRNA and protein levels. Mechanistically, LSI312A inhibited the phosphorylation of NF-κB, a central regulator of inflammatory responses, while promoting Nrf2 nuclear translocation, an essential factor in antioxidant signaling. Furthermore, LSI312A effectively suppressed the activation of the PI3K/Akt pathway, contributing to its anti-inflammatory effects. These results suggest that LSI312A modulates key inflammatory pathways and DC-mediated immune responses, highlighting its potential as a novel therapeutic candidate for inflammation-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.